Jeff Garro
Stock Analyst at Stephens & Co.
(0.90)
# 4,005
Out of 5,182 analysts
62
Total ratings
35%
Success rate
-12.84%
Average return
Main Sectors:
Stocks Rated by Jeff Garro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBRG TruBridge | Maintains: Equal-Weight | $20 → $18 | $25.72 | -30.02% | 4 | Apr 1, 2026 | |
| PHR Phreesia | Maintains: Overweight | $32 → $20 | $9.62 | +107.90% | 10 | Mar 31, 2026 | |
| HCAT Health Catalyst | Maintains: Equal-Weight | $3.5 → $2 | $1.37 | +45.99% | 5 | Mar 13, 2026 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $17 → $10 | $6.41 | +56.01% | 5 | Mar 6, 2026 | |
| DH Definitive Healthcare | Maintains: Equal-Weight | $3 → $2 | $1.01 | +98.02% | 2 | Feb 27, 2026 | |
| CERT Certara | Maintains: Overweight | $15 → $12 | $6.24 | +92.31% | 6 | Dec 12, 2025 | |
| PRVA Privia Health Group | Reiterates: Overweight | $32 | $24.41 | +31.09% | 6 | Dec 4, 2025 | |
| EVH Evolent Health | Reiterates: Equal-Weight | $9 | $3.47 | +159.37% | 6 | Sep 24, 2025 | |
| SLP Simulations Plus | Maintains: Overweight | $28 → $20 | $14.61 | +36.89% | 2 | Jul 15, 2025 | |
| VEEV Veeva Systems | Reiterates: Overweight | $280 | $160.45 | +74.51% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $55 | $24.66 | +123.03% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $250 | $163.84 | +52.59% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $16.39 | +3.72% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $28 | $5.85 | +378.63% | 2 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $20.95 | -4.53% | 3 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $5 → $3.9 | $8.10 | -51.85% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $0.92 | +226.83% | 3 | May 6, 2022 |
TruBridge
Apr 1, 2026
Maintains: Equal-Weight
Price Target: $20 → $18
Current: $25.72
Upside: -30.02%
Phreesia
Mar 31, 2026
Maintains: Overweight
Price Target: $32 → $20
Current: $9.62
Upside: +107.90%
Health Catalyst
Mar 13, 2026
Maintains: Equal-Weight
Price Target: $3.5 → $2
Current: $1.37
Upside: +45.99%
OptimizeRx
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $17 → $10
Current: $6.41
Upside: +56.01%
Definitive Healthcare
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.01
Upside: +98.02%
Certara
Dec 12, 2025
Maintains: Overweight
Price Target: $15 → $12
Current: $6.24
Upside: +92.31%
Privia Health Group
Dec 4, 2025
Reiterates: Overweight
Price Target: $32
Current: $24.41
Upside: +31.09%
Evolent Health
Sep 24, 2025
Reiterates: Equal-Weight
Price Target: $9
Current: $3.47
Upside: +159.37%
Simulations Plus
Jul 15, 2025
Maintains: Overweight
Price Target: $28 → $20
Current: $14.61
Upside: +36.89%
Veeva Systems
Mar 6, 2025
Reiterates: Overweight
Price Target: $280
Current: $160.45
Upside: +74.51%
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $24.66
Upside: +123.03%
Dec 20, 2024
Initiates: Overweight
Price Target: $250
Current: $163.84
Upside: +52.59%
Dec 9, 2024
Initiates: Buy
Price Target: $17
Current: $16.39
Upside: +3.72%
Jul 26, 2023
Reiterates: Equal-Weight
Price Target: $28
Current: $5.85
Upside: +378.63%
Aug 5, 2022
Maintains: Overweight
Price Target: $15 → $20
Current: $20.95
Upside: -4.53%
May 11, 2022
Maintains: Underweight
Price Target: $5 → $3.9
Current: $8.10
Upside: -51.85%
May 6, 2022
Maintains: Neutral
Price Target: $4 → $3
Current: $0.92
Upside: +226.83%